Data Supportive of Clinical Benefit of Niraparib Therapy in Patients With Ovarian Cancer

Preliminary data on time to first subsequent therapy (TFST) and progression free survival 2 (PFS2) were supportive of a clinical benefit of niraparib therapy in a broad population of patients with ovarian cancer following response to first-line chemotherapy, according to a study presented via the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer.

The objective of the study was to analyze whether niraparib improves PFS in patients with newly diagnosed advanced ovarian cancer after response to first-line platinum-based chemotherapy.

Seven hundred and thirty-three patients with newly diagnosed advanced ovarian, primary peritoneal, or fallopian tube cancer were randomized in a double-blind, placebo-controlled phase 3 study. The patients had to have a complete or partial response to first-line platinum-based chemotherapy.

Patients received niraparib or placebo once daily for 36 months or until disease progression. Overall, the median TFST was 6.6 months longer in patients receiving niraparib than in patients receiving placebo.

In patients with homologous-deficient tumors, median TFST had not been reached for those receiving niraparib, compared with 13.7 months in patients receiving placebo. The median TFST in patients with homologous recombination-proficient tumors was 3.7 months longer in patients receiving niraparib than in patients receiving placebo.

REFERENCE

Han SN, Monk BJ, Martin AG. Time to first subsequent therapy (TFST) and progression-free survival 2 (PFS2) from the phase 3 randomized, double-blind PRIMA/ENGOT-OV26/GOG-3012 study in patients with newly diagnosed ovarian cancer. SGO 2020. https://sgo.confex.com/sgo/2020/meetingapp.cgi/Paper/16306. Presented March 29, 2020. Accessed April 2, 2020.